Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 63Breast Neoplasms 63Carcinoma, Non-Small-Cell Lung 39Triple Negative Breast Neoplasms 29Ovarian Neoplasms 25Fallopian Tube Neoplasms 22Squamous Cell Carcinoma of Head and Neck 17Lung Neoplasms 16Stomach Neoplasms 11Neoplasm Metastasis 11Neoplasms 9Inflammatory Breast Neoplasms 9Breast Neoplasms, Male 9Melanoma 7Esophageal Neoplasms 7Cholangiocarcinoma 7Uterine Cervical Neoplasms 6Esophageal Squamous Cell Carcinoma 6Endometrial Neoplasms 6Carcinoma, Ovarian Epithelial 6Pancreatic Adenocarcinoma 5Gallbladder Neoplasms 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Recurrence 4Carcinoma, Transitional Cell 4Biliary Tract Neoplasms 4Prostatic Neoplasms 3Peritoneal Neoplasms 3

Interventions

sapanisertib 1Taxes 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Recurrent Malignant Solid Neoplasm × Taxes × Clear all
NCT03430882 2022-06-21

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
35 enrolled
Other solid neoplasm

Recurrent Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡